BioInvent International Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
107
- Stock Symbol
-
BINV
- Investments
-
3
- Share Price
-
$0.29
- (As of Friday Closing)
BioInvent International General Information
Description
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Contact Information
Website
www.bioinvent.comCorporate Office
- Ideon Science Park
- Ideongatan 1
- 223 70 Lund
- Sweden
Corporate Office
- Ideon Science Park
- Ideongatan 1
- 223 70 Lund
- Sweden
BioInvent International Stock Performance
As of 13-Nov-2026, BioInvent International’s stock price is $0.29. Its current market cap is $19.1M with 65.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.29 | $0.29 | $0.19 - $3.75 | $19.1M | 65.8M | 377K | -$0.79 |
BioInvent International Financials Summary
As of 30-Sep-2026, BioInvent International has a trailing 12-month revenue of $4.26M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 119,132 | 136,610 | 145,405 | 11,517 |
| Revenue | 4,255 | 23,054 | 4,225 | 6,723 |
| EBITDA | (49,840) | (33,798) | (42,689) | (33,945) |
| Net Income | (51,812) | (33,880) | (40,599) | (31,075) |
| Total Assets | 30,817 | 72,942 | 89,657 | 140,103 |
| Total Debt | 1,933 | 927 | 1,578 | 2,326 |
BioInvent International Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioInvent International Comparisons
Industry
Financing
Details
BioInvent International Competitors (31)
One of BioInvent International’s 31 competitors is Sareum Holdings, a Corporation company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sareum Holdings | Corporation | Cambridge, United Kingdom | ||||
| Coherus Oncology | Formerly VC-backed | Redwood City, CA | ||||
| Abliva | Formerly VC-backed | Lund, Sweden | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Active Biotech | Corporation | Lund, Sweden |
BioInvent International Patents
BioInvent International Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026082770-A1 | Antibodies against domain 4 of icam-1 and uses thereof | Pending | 16-Oct-2024 | ||
| EP-4537337-A1 | Methods of isolating anti-ligands | Pending | 13-Jun-2022 | ||
| US-20260018241-A1 | Methods of isolating anti-ligands | Pending | 13-Jun-2022 | ||
| WO-2023242125-A1 | Methods of isolating anti-ligands | Inactive | 13-Jun-2022 | ||
| WO-2023242125-A8 | Methods of isolating anti-ligands | Inactive | 13-Jun-2022 | G16B15/30 |
BioInvent International Signals
BioInvent International Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BioInvent International Investments (3)
BioInvent International’s most recent deal was a Corporate Asset Purchase with ThromboGenics (TB-403 rights). The deal was made on 01-Jan-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ThromboGenics (TB-403 rights) | 01-Jan-2017 | Corporate Asset Purchase | Buildings and Property | ||
| ThromboGenics (TB-403 rights) | 05-Jun-2012 | Corporate Asset Purchase | Buildings and Property | ||
| Cartela (Rights to Develop New Drug to Treat Osteoarthritis) | 16-Oct-2003 | Corporate Asset Purchase | Buildings and Property |
BioInvent International ESG
Risk Overview
Risk Rating
Updated November, 30, 2025
27.85 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
BioInvent International FAQs
-
When was BioInvent International founded?
BioInvent International was founded in 1996.
-
Where is BioInvent International headquartered?
BioInvent International is headquartered in Lund, Sweden.
-
What is the size of BioInvent International?
BioInvent International has 107 total employees.
-
What industry is BioInvent International in?
BioInvent International’s primary industry is Drug Discovery.
-
Is BioInvent International a private or public company?
BioInvent International is a Public company.
-
What is BioInvent International’s stock symbol?
The ticker symbol for BioInvent International is BINV.
-
What is the current stock price of BioInvent International?
As of 13-Nov-2026 the stock price of BioInvent International is $0.29.
-
What is the current market cap of BioInvent International?
The current market capitalization of BioInvent International is $19.1M.
-
What is BioInvent International’s current revenue?
The trailing twelve month revenue for BioInvent International is $4.26M.
-
Who are BioInvent International’s competitors?
Sareum Holdings, Coherus Oncology, Abliva, Bristol-Myers Squibb, and Active Biotech are some of the 31 competitors of BioInvent International.
-
What is BioInvent International’s annual earnings per share (EPS)?
BioInvent International’s EPS for 12 months was -$0.79.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process